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Complications of Vascular
Closure Devices—Not Yet Evidence Based
The interesting publication by Dangas et al. (1) claims to compare
arteriotomy closure devices with manual compression after percu-
taneous coronary intervention. Unfortunately, this is a comparison
only in the fashion that can be ascribed to a retrospective trial with
mismatched procedural variables and operator experience, ad hoc
recruitment, and broadly applied statistical techniques. The con-
clusion that closure devices are associated with a higher rate of
vascular complications could not possibly be ascertained from this
study. In fairness to the investigators, the segment of the inter-
ventional cardiology literature to which they have contributed is
largely a collection of testimonials and historical comparisons (2).
Unfortunately, there is a striking paucity of properly conducted
controlled clinical trials in this arena.
Our problems with this study (1) are multiple, some of which were
outlined in the accompanying editorial by Tavris et al. (3). First, the
investigators claim that “no large report exists on the ‘real world’
application” of these devices. Multiple studies have reported far larger
experiences, at least as “real world” as the investigators’ (4–6).
Second, Dangas et al., highly experienced and with an interna-
tional reputation in interventional cardiology, are largely novices at
vascular closure, having apparently declined to adopt them in
routine use. They include experience with only 6 Vasoseals, 32 Duetts,
and 6 Prostars; the majority of cases used Angioseals and Techstars.
The 516 deployments constitute only 8% of their cases, and amounts
to fewer than 150 cases per year, spread over multiple operators. In
contrast, the learning curve for one Perclose device as published by
Balzer et al. (6) appears to level off at approximately 350 cases.
Third, the individual operators may not have used the recom-
mended techniques for device deployment. For example, even
though femoral artery angiography “was recommended before
arteriotomy closure device application,” it was used only “in the
majority of cases” (we are not told the actual number). This is
clearly a disadvantage and probably inappropriate handling of the
devices, as numerous factors that predict outcome and might
demonstrate contraindications to device deployment were unknown
to the operators in what is likely a high percentage of the cases. Also,
because at least 13% and probably more of these femoral sticks were
not in the common femoral artery (regardless of the operators being
“very experienced with arterial puncture”), any number of the
pseudoaneurysms and retroperiotoneal bleeds could have been due to
misplacement of the femoral puncture (7). In the manual compression
group, such sins were much more easily masked when sheath pulling
took place at an activated clotting time (ACT) 150 s.
Fourth, prior published data have demonstrated that level of
anticoagulation, sheath size, physician learning curves, location of
puncture site, vessel size and presence of local atherosclerotic
disease all influence outcomes of vascular closure. The investigators
have demonstrated a mismatch in anticoagulation (ACT 277 vs.
150 s) and learning curves (experienced manual compression
technicians versus inexperienced closure device users). They do not
have the data regarding location of puncture site, atherosclerotic
disease or vessel size, and have failed to inform us regarding sheath
sizes other than that 10F sheath pulls were excluded. The latter
also raises the issue of possibly inappropriate use of closure devices
for larger than approved sheath sizes.
Fifth, Dangas and colleagues draw conclusions comparing two
sealing methods in a retrospective fashion using statistical methods
designed with the assumption that samples were selected at
random (8). Thus, the p values are misleading, adding to the
problems of this observational study with uncontrolled (retrospec-
tive) data acquisition, and ad hoc group assignment. These groups
are likely to have varied in ways the investigators did not notice or
chose to ignore, and these differences, rather than the treatment
modalities, may account for the potentially different outcomes.
Further, such studies can be subject to bias in completeness and
quality of information recorded in the hospital charts; the inves-
tigators reading such charts often must use considerable judgment
in assessing the data present. Sizing hematomas, for example, can
be difficult even in prospective studies and can be quite subjective
even with the most sophisticated measuring tools.
The study by Dangas et al. demonstrates that relatively novice
users of vascular closure devices, probably frequently not following
manufacturers’ recommendations, and deploying these devices in
fully anticoagulated patients, had a higher complication rate than
full-time employees trained to do manual compression who were
pulling sheaths when the ACT was 150 s. Perhaps the only truly
useful conclusion one could draw from the study (1) is that
operators should be well into their learning curve, should perform
an angiogram on the femoral artery before device deployment and
otherwise follow the recommended protocols before deployment in
fully anticoagulated patients. Although we use these devices after
percutaneous intervention in nearly 100% of our cases, we believe
that any recommendation should await the results of prospective
randomized studies applying uniform definitions of complications
and uniform measurement of end points.
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REPLY
We read with interest the letter of Schnyder and Turi, and are not
surprised that our study reporting increased complications associ-
ated with arteriotomy closure devices (ACD) has engendered such
a strong and obviously heartfelt response. When a negative study is
generated and subsequently published in the pursuit of academic
honesty and patient well-being (our overriding motivation), one must
regrettably anticipate one-sided and dogmatic reactions from parties
with possible academic, professional or commercial interests at stake.
Unfortunately, Schnyder and Turi have seemingly lost the “forest for
the trees” in their apparent zeal to promote this subspeciality. We shall
attempt to respond point by point to their critique.
The first generation ACDs were approved in the U.S. on the
basis of relatively small randomized trials designed to demonstrate
shorter times to hemostasis compared with manual compression in
patients undergoing diagnostic and interventional procedures.
None of these trials were powered to show differences in compli-
cation rates. Yet notwithstanding differing patient composition,
device sizes and complication definitions, all four studies showed
trends toward increased vascular complications with the ACD,
despite their application in the tightly controlled environment of a
clinical trial (Table 1).
We therefore examined our experience with closure devices in
patients undergoing percutaneous coronary intervention (PCI) at
the Washington Hospital Center, one of the busiest interventional
hospitals in the country, confirming significant increases in hema-
toma formation, large declines in hematocrit, and need for vascular
surgical repair with ACDs (1). Contrary to Schnyder and Turi’s
contention, this was not a “retrospective trial” subject to “bias in
completeness and quality of information recorded in the hospital
chart”; all data were prospectively collected by dedicated research
nurses, all field definitions were prespecified, and all adverse events
adjudicated. These quality measures far outstrip that of the usual
registry based either on retrospective chart review, or physician
recollection or documentation.
Schnyder and Turi are correct though in pointing out potential
hidden physician prejudices; the operators in the present study
were “biased” to tend to use these devices in ideal patients,
explaining why procedure duration was less in patients receiving
ACDs, and in whom less debulking and more stand-alone angio-
plasty were performed, requiring smaller sheaths (2). Nonetheless,
complications were still increased with closure devices despite
these predispositions favoring the ACD group. We further ac-
knowledge that the increased activated clotting time (ACT) levels
at the time of closure device insertion likely favored more bleeding
in the ACD group (1). However, the ability to withdraw sheaths
in the catheter laboratory in the fully anticoagulated patient, rather
than waiting 4 to 6 h for sheath extraction in the in-patient
telemetry unit prior to manual compression, is a purported advan-
tage of ACDs and the standard way these devices are utilized.
Certainly, Schnyder and Turi are not suggesting ACT normaliza-
tion is required before using a closure device, which would obviate
much of the device’s clinical desirability.
Schnyder and Turi criticize the physicians involved in this study
as being “largely novices at vascular closure, having apparently
failed to adopt them in routine use.” The great majority of the
closure procedures were performed by four senior physicians, who
collectively have performed 25,000 PCI procedures and many
more diagnostic angiograms. They note, however, that only 150
ACD procedures were being done per year in the study by these
physicians; this is true if only “interventional” procedures are
considered—the same four operators performed approximately
two- to threefold this many closure procedures annually on
diagnostic patients. Furthermore, the physicians involved have
been participating investigators in most of the premarket approval
ACD clinical trials. Thus, while we do not profess to possess the
expertise of Schnyder and Turi, the volume and experience with
ACDs represented in the present report certainly would more than
match the real-world qualifications of most centers experienced in
both traditional and novel methods of arteriotomy closure.
Schnyder and Turi also repeatedly note that not all patients in
our study had a preclosure femoral angiogram. Though we did not
collect this data, we believe 90% of patients did undergo such
examination, a frequency that is likely greater than at most
hospitals using ACDs in the “real world.” Indeed, one reason why
more patients did not receive closure devices in our study was the
low threshold in place to exclude patients upon the identification
of disease or calcification at the access site, an excessively low
puncture, or small vessel diameter. Furthermore, femoral angiog-
raphy was not performed in the manual compression group, and
cases unsuitable for closure devices on the basis of the angiogram
were also included in the manual compression group, both factors
that would favor the ACD group. Finally, to our knowledge, no
prior study (whether real-world or controlled trial) has ever
reported the actual frequency with which the recommended
femoral angiogram was in fact performed.
Schnyder and Turi state that “multiple studies have reported far
larger experiences” (2–4), taking issue with our statement that
large postapproval studies with these devices were lacking. At the
time of submission for publication, our analysis of 6,408 interven-
tional procedures was indeed the only large experience with 500
ACDs investigating femoral access complications after PCI; the
three referenced single-center studies were published afterward.
Regardless, these subsequent experiences largely support our find-
ings.
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